AlloVir Merges with Kalaris Therapeutics, Inc.

An announcement from AlloVir ( (ALVR) ) is now available.

On March 18, 2025, Kalaris Therapeutics, Inc. announced the completion of its merger with AlloVir, Inc., resulting in a combined company that will operate under the name Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker symbol ‘KLRS’ starting March 19, 2025. The merger has led to a change in the company’s stock ownership structure, with Legacy Kalaris stockholders owning approximately 74.47% and AlloVir stockholders owning about 25.53% of the combined company’s outstanding common stock. The merger is expected to provide Kalaris with approximately $100 million in cash, which will fund its operations into the fourth quarter of 2026, supporting the continued development of its lead product candidate, TH103, which is currently in a Phase 1 clinical trial.

More about AlloVir

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases. The company is developing TH103, a novel anti-VEGF investigational therapy aimed at treating neovascular and exudative diseases of the retina, including neovascular Age-related Macular Degeneration (nAMD).

Average Trading Volume: 22,633

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $29.71M

Find detailed analytics on ALVR stock on TipRanks’ Stock Analysis page.